SENTINEL LYMPH NODE BIOPSY IN BREAST CANCER: ONGOING CONSIDERATIONS
The status of axillary lymph nodes is a crucial prognostic factor in breast cancer. Currently, sentinel lymph node (SLN) biopsy is considered the gold standard for disease staging. This technique significantly reduces the extent of surgical intervention and helps avoid complete lymphadenectomy when no metastases are found in the SLN. Recent multicenter studies have demonstrated that SLN biopsy does not substantially impact oncological outcomes, supporting the trend toward de-escalating surgical treatment. This review analyzes publications from 2014 to 2024 available in the PubMed, Scopus, Web of Science, and eLibrary databases. It includes studies that assess the diagnostic accuracy and prognostic value of SLN biopsy, as well as its role in patients undergoing neoadjuvant chemotherapy, where accurate staging is crucial. Additionally, the review addresses the morphological aspects of SLN evaluation, such as the use of immunohistochemistry and molecular diagnostics to detect micrometastases and isolated tumor cells. Special attention is given to modern non-invasive approaches for preoperative SLN assessment, including the use of radiopharmaceuticals, fluorescence imaging, and artificial intelligence algorithms, which can enhance diagnostic accuracy and lessen the surgical burden on patients. Keywords: Breast cancer, sentinel lymph node, biopsy, adjuvant chemotherapy, neoadjuvant chemotherapy.
Сведения
- Журнал
- Avicenna Bulletin
- Опубликовано
- 2025 · Т. 27, № 3, С. 736-743
- Язык
- Английский
- ISSN
- 2074-0581 · 2959-6327
- Издатель
- Avicenna Tajik State Medical University